

23 March 2018

ACQUISITION BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG OF BIOTEST AG

Notice under section 96(2A) of the Enterprise Act 2002 (the Act) published pursuant to section 107(1)(i) of the Act

The Competition and Markets Authority (CMA) hereby gives notice pursuant to section 96(2A) of the Act that the merger notice provided by CREAT Group Co., Ltd. in relation to the acquisition by its indirect subsidiary Tiancheng (Germany) Pharmaceutical Holdings AG of Biotest AG (the **Merger**) meets the requirements of section 96(2) of the Act.

The initial period defined in section 34ZA(3) of the Act in relation to the Merger will therefore commence on the first working day after the date of this notice, ie on 26 March 2018. The deadline for the CMA to announce its decision whether to refer the Merger for a Phase 2 investigation is therefore 23 May 2018.

Raúl Nieto Assistant Director, Mergers Unit Raul.Nieto@cma.gsi.gov.uk